Abstract 326P
Background
Exercise is suggested to reduce the recurrence risk in individuals with breast cancer. Evidence regarding relevant physiological mechanisms remains scarce. Here, we examined the association of inflammatory biomarkers with predicted recurrence events.
Methods
The Optitrain randomized controlled trial consisted of 240 patients undergoing chemotherapy for primary breast cancer randomised to interventions entailing biweekly supervised concurrent resistance exercise and high-intensity interval training (RT-HIIT), or concurrent aerobic exercise and HIIT (AT-HIIT), or usual care (UC) between 2013-2016. At baseline and the one-year follow-up, 96 inflammatory protein biomarkers were assessed using the Olink® Proximity Extension Assay Oncology Panel. Group differences were estimated using analysis of covariance adjusted for baseline levels. Recurrence outcomes were obtained from National Swedish registers. Event probabilities were predicted from cox-proportional hazards models adjusted for age, menopause, BMI, tumour characteristics, and taxane treatment. Associations between survival probabilities and inflammatory markers were examined using Pearson’s correlation.
Results
When comparing RT-HIIT and UC, exploratory differences across several C-C-motif chemokine ligands were found (CCL2, CCL3, CCL4, CCL13, CCL20, CCL23). Moreover, DCN, ICOSLG, soluble CD8 and CD4, CX3SL1, CXCL10, CD70, CD83, CSF-1, HGF, NCR1, PD-L2, PIGF, PTN, TNFRSF12A, and TNFRSF21S differed across groups (p<0.2). When examining event probabilities, CD70, soluble CD4, CCL2, CCL3, CCL4, CCL13, CCL20, and CCL23 at the one-year follow-up examinations formed a cluster of a weakly increased risk in recurrence-related events. The strongest associations between event probabilities and biomarkers of inflammation were recorded for distant recurrence-free interval events.
Conclusions
Explorative analyses assessing the interplay of systemic inflammation, exercise, and predicted event probabilities suggested a cluster of inflammatory biomarkers affected by exercise and positively correlated with recurrence-related predicted event probabilities.
Clinical trial identification
NCT02522260, August 13, 2015.
Editorial acknowledgement
Legal entity responsible for the study
Region Stockholm.
Funding
1. The Swedish Cancer and Traffic Accident Foundation (CTRF) (grant number F-C-001225) 2. Swedish Cancer Foundation (grant number 130452) 3. Radiumhemmet Research foundation (grant number 131242) 4. Karolinska Institutet School of Caring Sciences (grant number 04960/2012).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays
Presenter: Federico Rojo
Session: Poster session 14
282P - Impact of pembrolizumab on ovarian function in young triple negative breast cancer patients treated with chemo-immunotherapy
Presenter: Anne Perdrix
Session: Poster session 14
283P - Immune-mediated secondary adrenal insufficiency is more commonly found in younger patients undergoing neoadjuvant treatment for early breast cancer
Presenter: Laura Lapuchesky
Session: Poster session 14
284P - Clinical and molecular characteristics of early-stage triple-negative breast cancer (eTNBC) patients with germline pathogenic variants in homologous recombination repair genes
Presenter: Adela Rodriguez Hernandez
Session: Poster session 14
285P - Adherence to endocrine therapy and sexual dysfunction in patients older than 65 years with early estrogen receptor-positive breast cancer
Presenter: Daniele Assad
Session: Poster session 14
286P - Impact of adjuvant endocrine therapy on survival outcomes in female breast cancer patients over 50
Presenter: Hanxiao Zuo
Session: Poster session 14
287P - Cognitive impairment in older breast cancer survivors
Presenter: Sharon Giordano
Session: Poster session 14
289P - Low risk febrile neutropenia: Does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Presenter: Jamie Weaver
Session: Poster session 14
290P - Subtype-specific prognostic value of lobular histology in patients with early-stage breast cancer: A nationwide population-based study
Presenter: Guilherme Nader Marta
Session: Poster session 14